bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
- None.
- None.
Insights
The biotechnology sector is closely monitored by investors for breakthroughs and advancements that can disrupt markets and provide substantial returns. bioAffinity Technologies' CyPath® Lung, a noninvasive test for early-stage lung cancer, addresses a critical medical need. The high sensitivity and specificity of the test could lead to significant market penetration given the projected growth of the lung cancer screening market to $5.7 billion by 2030. The Company's strategic move into COPD and asthma diagnosis, areas with a combined market size expected to reach $8.2 billion by 2027, demonstrates a forward-thinking approach to leveraging their technology across multiple respiratory diseases. The insider ownership at 39% signals confidence in the company's trajectory and may positively influence investor perception. However, the biotech industry is known for its high risk and the actual impact on the company's financials will depend on the successful commercialization and adoption of its technologies.
From a market perspective, bioAffinity Technologies' focus on early cancer diagnosis is strategically significant. Early detection is a key factor in reducing healthcare costs and improving patient outcomes, which aligns with broader healthcare trends towards preventative care. The U.S. Department of Defense's purchase of tests for research purposes could be indicative of the product's potential and may serve as a validation point for other institutional buyers. The company's expansion into COPD and asthma diagnostics, leveraging AI-driven data analysis, indicates an adaptive business model that could capture additional market share in the respiratory diagnostics sector. The global market for these conditions is substantial and growing, providing a lucrative opportunity for bioAffinity Technologies if their platform proves effective.
BioVie's focus on neurodegeneration and liver disease represents a significant area of unmet medical need, with potential for high-impact therapeutic advancements. The positive trending data from the Phase 3 trial in Alzheimer's disease for NE3107 suggests a promising future if the drug can achieve regulatory approval and market acceptance. Alzheimer's and Parkinson's diseases are areas with large patient populations and limited effective treatments, offering a substantial market opportunity. The planned Phase 3 trials in 2024 indicate a commitment to advancing their pipeline. The development of BIV201 for refractory ascites and HRS-AKI also targets conditions with high unmet medical needs, which could lead to expedited approval processes and market exclusivity benefits. Investors will be closely watching these trials, as successful outcomes could lead to significant stock price movements and industry repercussions.
ORLANDO, FL / ACCESSWIRE / January 5, 2024 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (NASDAQ:BIAF) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 5, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
- bioAffinity Technologies: https://www.redchip.com/assets/access/biaf_access
- BioVie: https://www.redchip.com/assets/access/bivi_access
In an exclusive interview, Maria Zannes, President and CEO of bioAffinity Technologies, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. bioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment. Its flagship product, CyPath® Lung, improves detection of early-stage lung cancer by analyzing the lung microenvironment. The noninvasive test has shown high sensitivity, specificity and accuracy. Lung cancer often goes undetected until it reaches late-stage when treatment options are less effective. Early detection increases survival and reduces medical costs. With commercialization underway, including a pilot program in Texas and the US DoD's purchase of tests for ongoing research, the Company is well-poised for growth. The lung cancer screening market is projected to reach
Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update. BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer's (AD) and Parkinson's (PD) and BIV201 for refractory ascites and HRS-AKI. BioVio recently reported data from a Phase 3 trial in AD that showed positive trending data showing that patients treated with NE3107 had treatment advantages compared to placebo on various cognitive, functional, and biomarker endpoints. The Company plans to launch Phase 3 trials in Alzheimer's, Parkinson's, and Ascites in 2024 and has multiple other efforts underway that may create additional catalysts.
About bioAffinity Technologies
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies, Inc. Research and optimization of the Company's platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn and X (Twitter).
About BioVie
BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer's and Parkinson's diseases. The Company is conducting a Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's. A Phase 2 study of NE3107 in Parkinson's disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in "morning on" symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com/.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Small Stocks Big Money® Show is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Small Stocks Big Money® Show," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
info@redchip.com
--END--
SOURCE: RedChip
View the original press release on accesswire.com
FAQ
What is the RedChip Small Stocks Big Money® Show?
What is CyPath® Lung?
What is NE3107 and BIV201?
What data did BioVie recently report from a Phase 3 trial in AD?
What are the future plans of BioVie?
What is the insider ownership percentage of bioAffinity Technologies?
